Paul F. Harron Jr. Lung Center

Interstitial Lung Disease (ILD) & Sarcoidosis: The Penn Difference

The Harron Lung Center is leading care for interstitial lung disease (ILD) beyond the limits of conventional medicine by offering patients more options to improve their lives. Penn is recognized across the country as a leader in ILD.

  • Penn developed the first clinic in the Philadelphia region dedicated to the care of patients with ILD.
  • Penn is one of only three centers in the country that treats beryllium disease, a lung disease caused by the inhalation of fumes or particles of beryllium, a common metal used in manufacturing. Harron Lung Center physicians invented the diagnostic test for beryllium disease.
  • Penn has one of only a dozen lymphangioleiomyomatosis (LAM) clinics in the country. LAM is a rare, progressive disease that strikes women, often during their childbearing years.
  • Penn is a member of the IPFnet, a network of research centers committed to studying idiopathic pulmonary fibrosis (IPF) under the guidance of the National Heart Lung and Blood Institute.
  • The Harron Lung Center leads clinical research and clinical trials for ILD to improve the standard of care, treatment and quality of life for patients diagnosed with lung cancer.